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Abstract
Background: Autoimmunity to the central nervous system (CNS) may play a pathogenic role in a subgroup of
patients with autism. This study aimed to investigate the frequency of serum anti-ganglioside M1 auto-antibodies,
as indicators of the presence of autoimmunity to CNS, in a group of autistic children. We are the first to measure
the relationship between these antibodies and the degree of the severity of autism.
Methods: Serum anti-ganglioside M1 antibodies were measured, by ELISA, in 54 autistic children, aged between 4
and 12 years, in comparison to 54 healthy-matched children. Autistic severity was assessed by using the Childhood
Autism Rating Scale (CARS).
Results: Autistic children had significantly higher serum levels of anti-ganglioside M1 antibodies than healthy
children (P < 0.001). The seropositivity of anti-ganglioside M1 antibodies was found in 74% (40/54) of autistic
children. Serum levels of anti-ganglioside M1 antibodies were significantly higher in autistic children with severe
autism (63%) than those with mild to moderate autism (37%), P = 0.001. Moreover, serum anti-ganglioside M1
antibodies had significant positive correlations with CARS (P < 0.001).
Conclusions: Serum levels of anti-ganglioside M1 antibodies were increased in many autistic children. Also, their
levels had significant positive correlations with the degree of the severity of autism. Thus, autism may be, in part,
one of the pediatric autoimmune neuropsychiatric disorders. Further wide-scale studies are warranted to shed light
on the possible etiopathogenic role of anti-ganglioside M1 auto-antibodies in autism. The role of immunotherapy
in autistic patients who have increased serum levels of anti-ganglioside M1 antibodies should also be studied.
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Background
Autism is a severe neurodevelopmental disorder that is
characterized by impairment in verbal and non-verbal
communication, imagination and reciprocal social
interaction. The prevalence of autism has surged in
recent years. The etiology of autism is not well under-
stood. Autism may occur as a result of exposure to
environmental factors in the presence of genetic pre-
disposition [1].
A possible role of immune system abnormalities in the
pathogenesis of some neurologic disorders, including
autism, was recently postulated. Autoimmunity to the
central nervous system (CNS) is the commonest of
these abnormalities [2,3]. The most important clue for
the possible role of autoimmunity in autism is the pre-
sence of brain-specific auto-antibodies in many autistic
children [3,4]. Other clues for the occurrence of autoim-
munity in autism include; the increase of autoimmune
disorders among autistic families [5-9]. Also, there is a
strong association between autism and the major histo-
compatibility complex for the null allele of C4B in class
III region. This results in low production of C4B protein
leading to repeated infections which play an important
role in the development of autoimmunity [10,11]. In
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of T-helper (Th)1/Th2 subsets toward Th2, which are
responsible for the allergic response and the production
of antibodies [2]. Furthermore, a new form of inflamma-
tory bowel disease, known as ileocolonic lymphonodular
hyperplasia or autistic enterocolitis, was reported in
some autistic children leading researchers to suspect a
gut-brain connection in autism [12].
Gangliosides are a family of sialylated glycosphingoli-
pids expressed in the outer leaflet of the plasma mem-
brane of the cells of all vertebrates. They are particularly
abundant in the nervous system and they are involved
in neurotransmission [13-16]. Gangliosides are thought
to play important roles in memory formation, neurito-
genesis, synaptic transmission, and other neural func-
tions [17,18]. The administration of exogenous
gangliosides seems to improve nerve regeneration [19].
Ganglioside M1 is the most abundant ganglioside in
neural membranes. It may be an autoantigen through
the galactose-galactosamine part of its sugar moiety
[20]. In humans, gangliosides elicit a T-cell independent
IgM response [21].
In immune-mediated neurological disorders, various
antibodies against neuronal tissues have been discov-
ered. Some of these antibodies have been found to cor-
relate with the pathomechanism of the disease [22]. The
key to establish the immunopathogenic role of the brain
auto-antibodies is to determine their effects on specific
brain functions[23].
Circulating anti-ganglioside M1 auto-antibodies may
play an etiopathogenic role in some autoimmune neuro-
logical disorders such as neuropsychiatric systemic lupus
e r y t h e m a t o s u s .T h e ym a yp l a yar o l ei nt h ec o g n i t i v e
dysfunction found in some lupus patients [24]. Further-
more, in axonal Guillain-Barré syndrome, antiganglio-
side antibodies may be produced by the mechanism of
molecular mimicry between gangliosides in the axon
and lipooligosaccharides of the antecedent infectious
pathogen [22,25].
Since autism may be one of the pediatric autoimmune
neuropsychiatric disorders, this study aimed to investi-
gate the frequency of serum anti-ganglioside M1 auto-
antibodies, as indicators of the presence of autoimmu-
nity to brain, in a group of autistic children. In addition,
we are the first to measure the relationship between
these antibodies and the degree of the severity of autism
which was assessed by using the Childhood Autism Rat-
ing Scale (CARS).
Methods
Study population
This case-control study was conducted on 54 children
who had classic-onset autism, over a period of 6 months
from the beginning of August 2010 to the end of
J a n u a r y2 0 1 1 .T h ea u t i s t i cg r o u pc o m p r i s e d4 7m a l e
and 7 female patients recruited from the Autism
Research and Treatment Center, Faculty of Medicine,
King Saud University, Riyadh, Saudi Arabia. Patients ful-
filled the criteria for the diagnosis of autism according
to the 4th edition of the Diagnostic and Statistical Man-
ual of Mental Disorders [26]. Their ages ranged between
4 and 11 years [median (IQR) = 9 (3) years]. Patients
who had associated neurological diseases (such as cere-
bral palsy and tuberous sclerosis) or metabolic disorders
(such as phenylketonuria) were excluded from the study.
The control group comprised 54 age- and sex-
matched apparently healthy children. They were the
healthy older siblings of the healthy infants who attend
the Well Baby Clinic, King Khalid University Hospital,
Faculty of Medicine, King Saud University, Riyadh,
Saudi Arabia for routine follow up of their growth para-
meters. The control children were not related to the
children with autism, and demonstrated no clinical find-
ings suggestive of immunological or neuropsychiatric
disorders. Their ages ranged between 4 and 11 years
[median (IQR) = 9 (4) years].
This study was approved by the local Ethical Commit-
tee of the Faculty of Medicine, King Saud University,
Riyadh, Saudi Arabia. In addition, an informed written
consent of participation in the study was signed by the
parents or the legal guardians of the all studied subjects.
Study measurements
Clinical evaluation of autistic patients
This was based on clinical history taking from care-
givers, clinical examination and neuropsychiatric assess-
ment. In addition, assessment of the degree of the
s e v e r i t yo fa u t i s mw a sd o n eb yu s i n gt h eC h i l d h o o d
Autism Rating Scale (CARS) [27] which rates the child
on a scale from one to four in each of fifteen areas
(relating to people; emotional response; imitation; body
use; object use; listening response; fear or nervousness;
verbal communication; non-verbal communication;
activity level; level and consistency of intellectual
response; adaptation to change; visual response; taste,
smell and touch response and general impressions).
According to this scale, children who have scored 30-36
have mild to moderate autism (n = 20, 37%), while
those with scores ranging between 37 and 60 points
have severe autism (n = 34, 63%).
Measurement of serum anti-ganglioside M1 antibodies
This was done by using ELISA kit for the specific mea-
surement of human total anti-ganglioside M1 in cell cul-
ture supernates, serum, and plasma (Uscnlife Science
and Technology Co., LTD). Monoclonal antibodies spe-
cific for ganglioside M1 had been pre-coated onto a
microplate. Standards and samples were pipetted into
the wells and any ganglioside M1 present was bound by
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antibody specific for gaglioside M1 was added to the
wells. Following a wash to remove any unbound anti-
body-enzyme reagent, a substrate solutionwas added to
the wells Color development was in proportion to the
amount of ganglioside M1 which was bound in the
initial step. The intensity of the color was measured. To
increase accuracy, all samples were analyzed twice in
two independent experiments to assess inter-assay varia-
tions and to ensure reproducibility of the observed
results (P > 0.05). No significant cross-reactivity or
interference was observed.
Statistical analysis
The results were analyzed by a commercially available
software package (Statview; Abacus Concepts, Inc., Berk-
ley, CA, USA). The data were non-parametric, thus they
were presented as median and interquartile range (IQR)
which are between the 25
th and 75
th percentiles. Mann-
Whitney test was used for comparison between these
data. Chi-square test was used for comparison between
qualitative variables of the studied groups. Spearman’s
rank correlation coefficient “r” was used to determine
the relationship between different variables. For all tests,
a probability (P) of less than 0.05 was considered signifi-
cant. The highest cut-off value of serum anti-ganglioside
M1 antibodies was 233 ng/ml (the 95
th percentile of the
control values as data distribution was non-parametric).
Results
Autistic children had significantly higher serum levels of
anti-ganglioside M1 antibodies [median (IQR) = 422
(486) ng/ml] than healthy controls [median (IQR) = 43
(75) ng/ml], P < 0.001 (table 1).
According to the highest cut-off value of serum anti-
ganglioside M1 antibodies, Increased serum levels of
anti-ganglioside M1 antibodies were found in 74% (40/
54) of all autistic children, in 55% (11/20) of patients
with mild to moderate autism and in 85% (29/34) of
children with severe autism.
Children with severe autism had significantly higher
serum levels of anti-ganglioside M1 antibodies [median
(IQR) = 592 (491) ng/ml] than patients with mild to
moderate autism [median (IQR) = 278.5 (321) ng/ml], P
= 0.001 (figure 1). In addition, the frequency of seropo-
sitivity of anti-ganglioside M1 antibodies was signifi-
cantly higher in patients with severe autism (85%) than
children with mild to moderate autism (55%), P = 0.01
(table 2). Moreover, serum levels of anti-ganglioside M1
antibodies of autistic patients had significant positive
correlations with CARS, P < 0.001 (figure 2).
All female autistic children had severe autism, while
only 57% of male autistic patients had severe autism.
Female autistic children had significantly higher serum
levels of anti-ganglioside M1 antibodies than male autis-
tic patients [median (IQR) = 875 (118) ng/ml and 356
(355) ng/ml, respectively], P < 0.001, (table 1). Although
the frequency of seropositivity of anti-ganglioside M1
antibodies was higher in fema l ea u t i s t i cp a t i e n t s( 1 0 0 % )
than male autistic children (70%), this difference was
not statistically significant (table 2).
Serum levels of anti-ganglioside M1 antibodies had no
significant correlations with the age of the autistic chil-
dren (P = 0.13).
Discussion
Aetiology of autism presents many challenging issues
and it has become an area of a significant controversy.
Autoimmunity may have a role in the pathogenesis of
autism [2,3]. Immune system dysfunction may represent
novel targets for treatment of autism [28].
In our series, autistic children had significantly higher
serum levels of anti-ganglioside M1 antibodies than
Table 1 Serum levels of anti-ganglioside M1 antibodies
in autistic patients and healthy children
Serum anti-ganglioside
antibodies
Median(IQR)
Z
(P)
Healthy children 43 (75) 6.43
Autistic patients 422 (486) (0.001)
Male autistic patients 356 (355) 4.22
Female autistic
patients
875 (118) (< 0.001)
IQR, interquartile range.
Figure 1 Serum levels of anti-ganglioside M1 antibodies in
relation to the degree of the severity of autism. Median values
are represented as horizontal bars.
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tivity of anti-ganglioside M1 antibodies was found in
74% of autistic children. We could not trace data in the
literature concerning the frequency of serum anti-gang-
lioside M1 antibodies in autistic children to compare
our results.
T h ep r e s e n c eo fo t h e rb r a i n auto-antibodies such as
anti-myelin basic protein antibodies and anti-myelin-
associated glycoprotein antibodies have been observed
in some autistic children [3,4]. In addition, the extracel-
lular mitochondrial DNA could act as an autoimmune
trigger because anti-mitochondrial antibodies type 2
were recently reported in blood of some autistic chil-
dren [29]. Despite of the fact that the origin of autoim-
munity in autism is unknown, immune related genes on
major histocompatibility complex, which have been
associated with some autoimmune diseases, may play a
central role in the development of autoimmunity in aut-
ism (e.g., HLA-DRB1 and C4B null alleles) [7,10,11].
Ganglioside M1 is the most abundant ganglioside in
the nervous system, in particular at synapses. It is
involved in the neurotransmission at the neuromuscular
junction [13-16]. Indeed, due to their location in the
nervous system, gangliosides could be a target molecule
in the complex autoimmune response [20]. They may
play a pathogenic role in autoimmune neurological dis-
orders [30]. Anti-ganglioside M1 antibodies are com-
monly found in the sera of patients with autoimmune
neurological disorders such as axonal Guillain-Barré
syndrome [22,25] and neuropsychiatric systemic lupus
erythematosus [24].
The reason behind the formation of some brain auto-
antibodies in some patients with autism is not fully
understood. It is speculated that an autoimmune reac-
tion to neurons might be trigged by some cross-reacting
antigens in the environment resulting in the release of
neuronal antigens. These neuronal antigens may result
in induction of autoimmune reactions through the acti-
vation of the inflammatory cells in genetically suscepti-
ble individuals. The environmental antigens may include
food allergies to certain peptides such as gliadin, cow’s
milk protein and soy [31] infectious agents [5], heavy
metals such as mercury [32] and Heavea Brasiliensis
proteins in natural rubber latex [33]. Cross-reacting
antigens in the environment may increase some adhe-
sion molecules on the brain endothelial cells. Pre-exist-
ing autoreactive T-cells may transmigrate across the
blood-brain barrier (BBB) and induce activation of local
antigen-presenting cells with production of cytokines
that may result in oligodendrocyte damage and demyeli-
nation. These events may result in the release of anti-
gens from neurofilaments that enter the circulation and
induce the formation of plasma cells which produce
antibodies against neuron-specific antigens. These anti-
bodies may cross the BBB and combine with brain tissue
antigens forming immune complexes that further
damage the neurological tissue [34].
In the present work, children with severe autism had
significantly higher serum levels of anti-ganglioside M1
antibodies than patients with mild to moderate autism,
P = 0.001. In addition, the frequency of seropositivity of
anti-ganglioside M1 antibodies was significantly higher
Table 2 The relationship between the frequency of the seropositivity of anti-ganglioside M1 antibodies and the
degree of the severity of autism and gender of autistic patients
Anti-ganglioside positive
(n = 40)
Anti-ganglioside negative
(n = 14)
X
2
(P)
Mild to moderate autism
(n = 20)
11
(55%)
9
(45%)
6.02
Severe autism
(n = 34)
29
(85.3%)
5
(14.7%)
(0.01)
Male autistic patients
(n = 47)
33
(70%)
14
(30%)
2.82
Female autistic patients
(n = 7)
7 0 (0.1)
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Figure 2 Positive correlations between serum levels of anti-
ganglioside M1 antibodies and the degree of the severity of
autism. CARS, the Childhood Autism Rating Scale.
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mild to moderate autism (55%), P = 0.01. Moreover,
serum levels of anti-ganglioside M1 antibodies of autis-
tic patients had significant positive correlations with
CARS, P < 0.001. This may indicate that the extent of
the elevation of serum anti-gnglioside M1 antibodies
was possibly linked to the degree of the severity of aut-
ism assessed by CARS. All female patients had severe
autism, while only 57% of the male patients had severe
autism, this may explain the significant increase of
serum anti-ganglioside M1 antibodies in female patients
compared to male patients (P < 0.001). The relationship
between anti-ganglioside M1 antibodies and the severity
of autism is possibly a causal one, in which these auto-
antibodies might be playing a role in the pathogenesis of
brain damage, the extent of which may determine the
clinical severity of autism. Thus, further studies, on a
large scale, are warranted to reveal if anti-ganglioside
M1 antibodies have a role in the pathogenesis of autism.
Previous research reported an increased frequency of
autoimmune diseases in families of autistic children
compared to those of healthy control subjects [5-9].
This may be an outstanding feature among autistic
patients that points to their autoimmune background;
the target in their case being the developing brain. This
implies that in some families, immune dysfunction, per-
haps induced by certain environmental triggers, could
express itself in the form of autism in one of its off-
s p r i n g s .T h eh i g hr a t eo fa u t o i m m u n ed i s e a s ei nt h e
mothers of the children with autism [5-9] could also
suggest that an autoimmune process exists in the
mothers that is targeted toward the developing fetus in
utero. Although this would be more consistent with the
female preponderance in autoimmune disorders, it does
not explain the high male to-female ratio observed in
autism [35].
To date, a definitive relationship between autism and
autoimmunity has not been fully established. On the
basis of the preliminary results reported in this study,
t h e r es e e m st ob eas u g g e s t i v ee v i d e n c ei ns u p p o r to f
autoimmune contributions to the pathophysiology of
autism in some cases. Additional investigations designed
to expand on these data are warranted.
Therapy in patients who are seropositive for serum
auto-antibodies is directed at reducing the concentration
of these antibodies, blocking the effector mechanisms
and depleting the monoclonal B cells. The recent avail-
ability of a monoclonal antibody suppressing B-cell
clones, which is not myelosuppressive and does not cause
secondary malignancies, allows for early targeted inter-
vention [36]. Preliminary results suggest that this new
line of therapy is well tolerated and is promising in the
treatment of some patients [37,38]. Therefore, the role of
this new line of therapy in autistic patients who have
increased serum anti-ganglioside M1 antibodies should
be studied. The administration of exogenous gangliosides
seems to improve nerve regeneration [19]. Therefore,
studies concerning the possible role of the administration
of exogenous gangliosides in the amelioration of some
autistic manifestations should also be conducted.
Conclusions
Serum levels of anti-ganglioside M1 antibodies were
increased in many autistic children. Also, their levels
had significant positive correlations with the degree of
the severity of autism. Thus, autism may be, in part, one
of the pediatric autoimmune neuropsychiatric disorders.
Further wide-scale studies are warranted to shed light
on the possible etiopathogenic role of anti-ganglioside
M1 auto-antibodies in autism. The role of immunother-
apy in autistic patients who have increased serum levels
of anti-ganglioside M1 antibodies should also be studied.
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